These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25395371)

  • 1. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
    Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.
    Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A
    Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
    Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A
    Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
    Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
    Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
    Torii Y; Sasaki M; Shin MC; Akaike N; Kaji R
    Toxicon; 2018 Oct; 153():114-119. PubMed ID: 30193802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
    Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
    J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of alternative potency test for botulinum toxin type A using compound muscle action potential (CMAP) in rats.
    Torii Y; Goto Y; Nakahira S; Ginnaga A
    Toxicon; 2014 Nov; 90():97-105. PubMed ID: 25110177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.
    Takeuchi T; Okuno T; Miyashiro A; Kohda T; Miyamoto R; Izumi Y; Kozaki S; Kaji R
    Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical differences between A1 and A2 botulinum toxin subtypes.
    Kaji R
    Toxicon; 2015 Dec; 107(Pt A):85-8. PubMed ID: 26394198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats.
    Sakamoto T; Torii Y; Takahashi M; Ishida S; Goto Y; Nakano H; Harakawa T; Ginnaga A; Kozaki S; Kaji R
    Toxicon; 2009 Nov; 54(6):857-61. PubMed ID: 19559720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins.
    Torii Y; Goto Y; Takahashi M; Ishida S; Harakawa T; Sakamoto T; Kaji R; Kozaki S; Ginnaga A
    Toxicon; 2010; 55(2-3):407-14. PubMed ID: 19778548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
    Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
    Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test.
    Kim SH; Kim SB; Yang GH; Rhee CH
    Toxicon; 2012 Sep; 60(3):341-7. PubMed ID: 22613167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of biological activity of four botulinum toxin type A preparations in mice.
    Chung ME; Song DH; Park JH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
    Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.
    Akaike N; Shin MC; Wakita M; Torii Y; Harakawa T; Ginnaga A; Kato K; Kaji R; Kozaki S
    J Physiol; 2013 Feb; 591(4):1031-43. PubMed ID: 23109108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).
    Torii Y; Takahashi M; Ishida S; Goto Y; Nakahira S; Harakawa T; Kaji R; Kozaki S; Ginnaga A
    Toxicon; 2010; 55(2-3):662-5. PubMed ID: 19781565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.
    Aoki KR
    Toxicon; 2001 Dec; 39(12):1815-20. PubMed ID: 11600142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model.
    Cichon JV; McCaffrey TV; Litchy WJ; Knops JL
    Laryngoscope; 1995 Feb; 105(2):144-8. PubMed ID: 8544593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle.
    Kim CS; Jang WS; Son IP; Nam SH; Kim YI; Park KY; Kim BJ; Kim MN
    Hum Exp Toxicol; 2013 Sep; 32(9):914-20. PubMed ID: 23475433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.